Psychoactive Substances Bill [Lords]

Cheryl Gillan Excerpts

Wednesday 20th January 2016 Commons Chamber

[Mrs Cheryl Gillan (Chesham and Amersham) (Con)]

The hon. Lady may not be aware that a very prominent anti-drugs campaigner in my constituency, Mary Brett, has always had a lot of problems with the FRANK website, particularly because of its emphasis on harm reduction. The feeling is that the website fails to really point out the dangers in a direct way that youngsters can understand. I therefore rise to support the hon. Lady in hoping that the Minister will re-examine this issue, because many very good campaigners with honestly held views think that FRANK is not good enough.

[Lyn Brown]

I thank the right hon. Lady for making that point. I know very little about drugs, apart from what I have learned hard over the past few months. I did not even know what poppers were when I first took on my brief—I had never heard of them; I thought they were the little things with the string that we had at parties. When I looked at the FRANK website it did not enlighten me that much. I needed something a bit more basic that would help to enlighten and educate me, and I therefore agree with the point she has made.

I urge the Minister to accept my amendment 4 and pledge to report to Parliament on the progress made in delivering the Government’s education strategy. It really is not a big ask and if the Government are serious about drugs education—I genuinely believe that the Minister for Policing, Crime and Criminal Justice is—they ought to be committed to monitoring this rigorously, at the very least. He claimed in his letter to the Bill Committee that the statutory review should focus on the operation of the legislation. I agree, but the operation of this legislation will not happen in a vacuum. He has repeatedly said that it must be complemented by a communication and awareness strategy. It therefore seems appropriate to me that a look at the “operation” of this legislation would include a substantive section on education and awareness, just to make sure that we are getting the messages out there and reducing demand.

I am sure the Minister will agree that we should be keen to review and evaluate the impact this legislation will have, and I am pleased there is provision in the Bill to ensure that that will happen. However, will he provide assurances that in the regular and annual collection of statistics about arrests, prosecutions, sentencing, offender management and treatment, information collected about substances covered by this legislation will not be subsumed into the similar data collected for drugs controlled under the Misuse of Drugs Act 1971? Similarly, will he confirm that surveys carried out by the Government on crime and public health will separate out the consideration of information about the Misuse of Drugs Act controlled drugs and of information about psychoactive substances? I raise that matter because it will be too easy simply to obscure the impact this legislation will have if the information is collapsed into the existing systems for collecting data about action taken on drugs controlled under the Misuse of Drugs Act.

I would also like the Minister to accept new clause 1—a girl can dream! The Government’s approach to PSHE simply is not working and we cannot stand by and let that happen when new psychoactive substances are bringing new dangers into our communities.

While I am on my feet, I will also speak to amendment 5, which, if passed, will add poppers to the list of exemptions to the ban on psychoactive substances. Poppers would then be treated like nicotine, alcohol and caffeine—substances that we know to be psychoactive, but do not feel it judicious to ban. We support the Bill because legislation is necessary to safeguard against the serious harms created by new psychoactive substances. Our concern to safeguard against harm is exactly why we believe that poppers should be exempt from the ban on psychoactive substances. In our judgment, fewer harms are likely to occur if poppers are added to the exemption list.

--- Later in debate ---

[Mrs Gillan]

Amendment 1, which stands in my name, is a probing amendment, as I wish to ascertain the Government’s position on a number of products marketed by a constituent of mine through an online marketing company called Focus Supplements. Several weeks ago he came into my constituency surgery. He was very concerned that the products he sells, quite legally—they are effectively health supplements used for various reasons, which I will talk about later—might fall within the ambit of the Bill.

I want to ensure that the Minister and the Department know that there are substances out there that are being marketed by perfectly honest, decent and legal companies, such as Holland & Barrett, and indeed on eBay, that might fall within the ambit of the Bill. It might criminalise substances that are perfectly innocuous, and indeed that are in some demand. I have no personal experience of those products, and I am very supportive of this Bill, so I would not have tabled the amendment or asked for clarification from the Minister if I thought that the substances I have listed would lead to any harm. The purpose of my amendment is to see whether those substances might fall foul of the Bill, and indeed whether clause 3, which has already been discussed, can be fleshed out at this stage, as that would help people listening to the debate.

Many of these products are used by people to combat anxiety, to aid sleep, to enhance memory and learning and to improve focus, and as such they are used as dietary supplements. Cholinergics increase choline in the brain and contain a substance that is found naturally in many foods—foods rich in choline include smoked salmon, fried eggs, chicken livers and Brussels sprouts. Indeed, there are recommendations in some health regimes around the world that people should take a certain level of choline every day in their diet.

Racetams—I hope I am pronouncing these correctly—are sometimes called nootropics. They can in some cases improve one or more functions of the brain. They can improve working memory, motivation or even attention—perhaps Members of this House should take such supplements to improve their attention in some debates. Various products are listed in the amendment as miscellaneous. Oxitriptan, a precursor for serotonin, is sold in health shops such as Holland & Barrett. L-Theanine is found in green tea and is available from companies such as Nature’s Best. Tongkat Ali is available from various health shops. Resveratol, I am reliably informed, is an excellent substance that is found in red wine. Sulbutiamine is two thiamine—vitamin B1—molecules.

When my constituent, Jack Baldwin, met the MHRA, it indicated it was perfectly legal for him to sell those products, but it stressed it was important that no medicinal claims was made for them. Indeed, in many other countries, including the USA, none of the substances listed in amendment 1 are controlled substances and it is perfectly legal to use, own and sell all of them. One of the problems with a lot of these products is that they are relatively young—only 10 years old in some cases. Although many have been subject to studies at academic level, they have not gone through the rigorous testing that medicinal drugs would necessarily go through. Nevertheless, they do not seem to be the sort of products that this Government or this Minister are seeking to ban.

[Mr David Davis]

My right hon. Friend is exactly right, for two reasons. First, many fitness supplements and other supplements work through the brain. There is no doubt about that—growth hormone-related ones do, and benign things like sage oil do. The other problem she faces is in the definition in the explanatory notes, which says that a psychoactive substance is a substance that causes

“a range of effects including, but not limited to hallucinations; changes in alertness, perception of time and space, mood or empathy with others; and drowsiness.”

All of those could apply to everything from antihistamines to, as I say, something as benign as sage oil. The problem is that if we are not careful we will end up with bad law that will undermine the status of people such as her constituent.

[Mrs Gillan]

I could not put it better myself. That is what concerns me about the Bill. The point was made that if this is seen to be a blanket ban—and a stupid ban because it bans perfectly innocuous substances—that will undermine the very purpose for which the law is being passed.

[Paul Flynn]

Does not the right hon. Lady think that if we treat these nootropic drugs differently from all the other new psychoactive drugs, there is a danger that we give them some credibility or approval? There has been some research into their harm, or otherwise. The trials have been poorly designed, and they have not found any great dangers in them, but they would not be accepted as being right for a medicinal drug. I understand her constituent’s commercial interest, but would it not be dangerous to treat this group the same as any other and thereby give the public the impression that they are harmless, because we do not know that?

[Mrs Gillan]

I do not think that putting them on the exempted list means that anybody should draw the conclusion that they are harmless. They obviously have an effect of some sort on individuals; otherwise, my constituent would not have, as he reports to me, 32% repeat orders for many of these substances. I take the hon. Gentleman’s point. However, in relation to cholinergics, the National Academy of Sciences has said that choline is a dietary requirement, as I mentioned, and the Food and Drug Administration has recommended 425 milligrams of choline intake a day. With regard to racetams, oxiracetam, for example, has been shown to improve step-down, retention and acquisition performance in research carried out on rats, I believe, and was supported in a paper in “Behavioural Brain Research” in 1996. I have various other references citing good research carried out into these drugs; some, I admit, have not had so much research into them.

The purpose of amendment 1 is to make sure that the law of unintended consequences does not apply to this Bill. The Minister needs to reassure my constituent, and the many organisations such as online companies and health food shops that sell these substances, that either they do not fall within the ambit of this Bill, and that therefore they need not concern themselves about falling foul of it, or, if he thinks that these substances need more research, to tell us what needs to be done. I expect, at the bare minimum, that he will undertake to review the products that I have listed in the amendment and to let us know, after discussions with the ACMD, what he intends to do. I hope that he will be able either to add these products to the exempted list or to let us know that the Bill does not apply to them. If it does not, he needs to reassure my constituent by letting me know the timescales within which he will investigate these products and perhaps others that might be brought to his attention.

[Keith Vaz (Leicester East) (Lab)]

It is a pleasure to follow the right hon. Member for Chesham and Amersham (Mrs Gillan), who is one of the most distinguished and respected Members of this House, and makes her case very powerfully. I owe her an apology. Because of the speed with which the Home Affairs Committee had to look at the Bill, owing to the timetable that the Government gave us, we did not have the opportunity to explore properly the points she has made or to take evidence from her constituent and others who might have felt that they were going to be affected by it. If we had had more time, we certainly would have had them before us. I am sure that, as is our policy, when we come to review this Bill in a few months’ time we will have the opportunity to consider exactly what its effect has been. I thank her for tabling the amendment and for reminding the House of the importance of all the other products that might be caught by the Bill.

I want to commend the Minister, who is rapidly becoming one of my favourite Home Office Ministers, partly because he agreed to be Father Christmas at the Westminster kids club party, and did it so well, but also because he is prepared to listen to the House. He said he would look at the work of the Select Committee and try to reflect some of it in the amendments he tabled in Committee, and he did so in the case of many of our recommendations. Yesterday he sent me—I thank him for giving me plenty of time to read it for today’s debate—the Government’s response to the Bill’s Committee stage and to our recommendations.

I thank the hon. Member for Enfield, Southgate (Mr Burrowes) for last year pushing the Select Committee to hold an inquiry before the House had to consider the Bill on Second Reading. Again, we were caught out by the Government’s timetable being moved forward, as a result of which we did not have all the time in the world to consider these things. However, I thank him for doing it. I thank members of the Bill Committee, some of whom are here today, for the work they did at very short notice to ensure that that happened. The hon. Member for Louth and Horncastle (Victoria Atkins) attended many of the Committee’s sittings despite the fact that she was serving on two other Committees at the same time.

The Government have moved on several of the points that we have made. They were right to legislate—there is no question about that. This has been in the in-tray of successive Home Office Ministers for a number of years. The previous Labour Government were committed to doing something about it—it was in our manifesto, as our excellent shadow Home Office Minister said—and I am sure that if the votes had fallen in the opposite direction, we would have a Labour Minister introducing a similar Bill. I therefore say well done to the Minister for doing this and for incorporating most of what we have suggested.

I particularly want to talk about amendments 1 and 5. It is very important that we give support to voluntary organisations such as the Angelus Foundation, which invariably know more than Government, because they draw on the experience of real, live people, and they are prepared to come together voluntarily to try to warn the public and Parliament about the risks of these substances. I am glad that we are not using the term “legal highs” any more, because, as the report clearly says, that encourages people to want to try them.

I agree very much with the shadow Minister’s comments about education, which I am sure the Minister will echo. We cannot do too much to persuade young people that they should not be taking these substances. My children are 20 and 18, and they are away at university. It is every parent’s nightmare that one of their children, on a night out after studying and doing their work, will be offered a substance that is perfectly legal, take it, and then be ill and, in some cases, die. The Home Affairs Committee therefore absolutely support the Government’s tough approach.

--- Later in debate ---

[Dr Poulter]

My hon. Friend is right.

I shall speak, first, about the barriers to mental health research—we know that the use of cannabis has links with mental illness, particularly psychosis—and also about the broader research into the potential medicinal benefits of the many products contained in the cannabis plant. That has been investigated in the United States, where more than 20 states have relaxed their laws to allow the medicinal use of cannabis and cannabis derivatives. I am pleased to hear that the all-party group is to look into that because it is important that we examine the evidence that is out there and, if necessary, consider using that evidence to change the law. The law should be for public protection but also for public benefit, and if there is a legitimate medicinal use of cannabis, we should support and encourage it because that is good for patients.

Before I proceed, I want to touch on the very brave speech from my hon. Friend the Member for Reigate (Crispin Blunt). It is rare that we discuss our personal experiences in the Chamber, but it brings into focus the importance of making sure that the laws that we pass impact positively on the real world and the day-to-day lives of our constituents. He spoke bravely about his own use of poppers, which helped to bring the debate alive and crystallised the importance of that evidence-based policy making. I know the Minister will respond to that later.

On the rescheduling of cannabis from a schedule 1 to a schedule 2 drug, as we are aware, the scheduling of drugs was laid down in the Misuse of Drugs Regulations 2001. The reason that cannabis was considered a schedule 1 drug was that it did not have any medicinal benefit. That is now a matter of considerable contention in the light of the evidence I am about to present. It is important to highlight some of the inconsistencies in legislation.

Under the Schengen agreement, it is legal for somebody in a Schengen country to bring into the UK cannabis for medicinal use, if they have been prescribed it by a doctor on their own country, for up to 30 days, yet it is not legal in this country for a doctor to prescribe cannabis for medicinal purposes unless it happens to be for the purpose of treating multiple sclerosis. That is the one licensed drug currently available. If we recognise that cannabis can be licensed for the treatment of MS, currently under very elaborate licensing law by the Home Office, surely we recognise that there is a medicinal benefit. Quod erat demonstrandum: schedule 1 is the wrong place for cannabis because we accept that it has a medicinal benefit. The Home Office accepts for its licensing programme that there is a medicinal benefit to cannabis, so we need to consider rescheduling the drug.

I have touched on the intervention from my hon. Friend the Member for Winchester (Steve Brine) by reference to the growing evidence from the United States that there are other potential medicinal benefits of cannabis for the treatment of patients. The relaxing of laws in over 20 states on the basis of that evidence is something that we clearly need to look at in this country. In particular, the potential benefits of cannabis products in palliative care merit greater scrutiny. There is inconsistency in the classification of cannabis, which is why I tabled the amendment.

I want to speak about some of the barriers to research. I am very grateful to my right hon. Friend the Minister for Policing, Crime and Criminal Justice for meeting Professor Sir Robin Murray—he is an eminent professor—and Dr Marta Di Forti, who work in mental health, particularly in psychosis, to examine the issue and learn at first hand about some of the difficulties they experience in conducting research into mental ill health. We know that there are links between psychosis and cannabis use, and it is particularly important that we understand the basis on which the plant works on neurotransmitters and that we support researchers in conducting their research. At the moment, those researchers could potentially be criminalised for carrying out research that would be legitimate in many other fields of medical research. I am sure that that is not an intended consequence. It also makes it very difficult to carry out research effectively in the field of mental health and the links with cannabis. I know that the Minister is sympathetic to that and I look forward to hearing how we can find a workable solution to the problem. We want to improve our treatment of patients with mental ill health, but to do that we need properly to support the researchers in carrying out their work, and I hope that the whole House can sign up to that.

This is not an easy matter and it is not part of a broader discussion on the merits or demerits of legalising cannabis. I specifically wanted to table the amendment for discussion today to highlight the difficulties faced by researchers carrying out their jobs and to highlight some of the clear inconsistencies in drug laws in relation to cannabis and, more importantly, drugs that we would consider much more potentially harmful if used by the public. Heroin, or diamorphine, is a schedule 2 drug, whereas cannabis, the use of which is shown by a growing body of evidence to have a medicinal benefit, is a schedule 1 drug. I believe that the Government need to look into the inconsistency in current drug laws, but in particular I would be very grateful for my right hon. Friend the Minister’s comments on how we can facilitate and ease the process of legitimate research without criminalising researchers.

[Mrs Gillan]

Does my hon. Friend also agree that there is a real anomaly when a drug such as DNP, which has caused the death of so many young people and is taken as a drug for body building or to improve people’s perception of their body image, is so classified and falls between so many stools that it is impossible to get it banned, despite the deaths and damage it has caused?

[Dr Poulter]

My right hon. Friend speaks wisely. On that subject, looking at the scheduling, steroids come under schedule 4 to the misuse of drugs regulations. They are often a drug misused by body builders and other athletes whereas, in the example I just gave, diamorphine, or heroin, is a schedule 2 drug. There is now a clear and compelling case, because of the growing medical evidence and the barriers to research, to consider the scheduling of cannabis. More broadly, before we even get to that point, I know that there is more we can do to make it easier to research the links between cannabis and mental health and to support that very important research so that, hopefully, we can move towards a better position through this Bill, not just in protecting the public from psychoactive substances but in improving the care of a number of the most vulnerable patients looked after by our health service.

I intend the amendment as a probing amendment and do not wish to press it to a vote, but I look forward to hearing my right hon. Friend the Minister’s response.

--- Later in debate ---

[Mike Penning]

Let me make some progress. If I have time, I will come back to the right hon. Gentleman.

I know from the speech of my right hon. Friend the Member for Chesham and Amersham (Mrs Gillan) that there were concerns that non-psychoactive substances will be pulled in. This Bill is specifically about psychoactive substances. My full understanding is that we will not be including the sort of products to which she has alluded, but we will keep a close eye. Under clause 3, we have the ability to take things out. I must say, though, that that clause is not designed to bring in things, which caused slight confusion during the debate this afternoon. When I come on to poppers, I will explain myself a little better.

[Mrs Gillan]

Will the Minister give way?

[Mike Penning]

No, I want to make some progress if I can, but I will come back if I have some time.

Last night, I had the honour of meeting my hon. Friend the Member for Central Suffolk and North Ipswich (Dr Poulter), along with a professor from King’s, to discuss research. We need research not only in matters of health, but in the law to ensure that we are evidence based. I was conscious last night that we needed to ensure that we are not preventing research. The Bill actually makes a provision for it, but the probing amendments of my hon. Friend were looking at the problems around cannabis and how we need to learn about its harms and benefits. I will ask my officials to continue that important dialogue after we leave the Chamber this afternoon.

I had a really interesting time in Committee with the Scottish National party’s Front-Bench spokesperson, the hon. Member for Glasgow North East (Anne McLaughlin). We have had a very good dialogue with Scottish Ministers, particularly on an important provision that makes possession a criminal offence in secure facilities. That was not originally in the Bill, but it was added at the request of the Ministry of Justice and, interestingly, prison officers and some prison groups, because these substances are a menace in our prisons and young offenders institutions. I am quite amazed at some of the hon. Lady’s amendments today, because during our discussions both the Minister and the Cabinet Secretary in the Scottish Government were content for possession in custodial suites to be an offence. I make no comment on communications within the Scottish Administration, but we worked really hard to ensure that everybody was on board with that, so I cannot support those amendments.

The key to the Bill is protecting people. I do not want to criminalise every young person in the country who has been using these substances legally, but dangerously, for a considerable time. However, it is absolutely crucial that we do not get into a situation in which the defence in our courts is, “I bought it for a couple of friends and sold it on to them, so what’s the danger?” It is a danger.

[Mrs Gillan]

In that case, will the Minister ensure that he writes to me about the substances listed in my amendment so that I can reassure my constituents that they will not be breaking the law by continuing to offer them online?

[Mike Penning]

I am more than happy to write to my right hon. Friend with those assurances, so long as we know exactly what those substances are. We need to communicate about that outside the Chamber.